Ofatumumab
Based on 1 Customer Validation
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.54%
- CAS No.: 679818-59-8
- Masse moléculaire:145.94 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
CD20/MS4A1
Ofatumumab (10 μg/mL; 6 h) significantly induces cell lysis in a complement-dependent cytotoxicity (CDC) assay of mantle cell lymphoma (MCL) cell lines, with an effect superior to that of Rituximab (HY-P9913), and is still active against resistant cells with low CD20 expression or high complement inhibitory protein (CD55/CD59) expression[1].
Ofatumumab (10 μg/mL; 24-72 h) has direct killing of B-cell lymphoma cell lines, with an inhibitory effect similar to that of Rituximab[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mantle cell lymphoma (MCL) cell lines (Granta, HBL-2, Jeko-1, Mino, Rec-1, Z-138)
-
Concentration:10 μg/mL
-
Incubation Time:6 h
-
Result:Cell Lysis : Induced higher CDC-mediated lysis compared to rituximab in all tested cell lines except Granta, with significant differences in Mino, Rec-1, and Jeko-1 cells. For example, in Mino cells, achieved 65% lysis vs. 35% with rituximab.
Resistance Mechanisms : Cells with high CD55/CD59 expression (e.g., Raji-4RH) showed reduced rituximab-induced lysis, but Ofatumumab maintained efficacy, indicating less dependency on CD20 density.
-
Cell Line:B-cell lymphoma cell lines (Mino, Rec-1, HBL-2, Raji, RL)
-
Concentration:10 μg/mL
-
Incubation Time:24, 48, 72 h
-
Result:Cell Viability : Both antibodies caused time-dependent viability reduction, with Ofatumumab showing comparable activity to rituximab across most cell lines.
A significant difference was observed in Mino cells at 72 h, where Ofatumumab reduced viability to 30% vs. 45% with Rituximab.
Direct Cytotoxicity : Flow cytometry and immunofluorescence revealed no significant differences in apoptosis or cell cycle arrest between the two antibodies, suggesting minimal direct cytotoxic effects beyond immune-mediated lysis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female SCID mice (6-8 weeks old, ~20 g) + subcutaneous xenograft model of human mantle cell lymphoma (Z-138 cells)[1]
-
Dosage:10 mg/kg (dissolved in sterile saline)
-
Administration:Intravenous injection via tail vein; 4 doses on days 0, 3, 7, and 10 post-tumor engraftment
-
Result:Significantly delayed early tumor progression compared to rituximab. Tumor volume in the ofatumumab group remained smaller than 500 mm3 for over 80 days, whereas the rituximab group showed progressive growth exceeding 2000 mm3 by day 120.
Resulted a median survival time of >90 days in the ofatumumab group (median not reached by study end), compared to 127 days in the Rituximab group.
Reduced tumor cellularity and increased apoptotic cells in of Atumumab-treated mice, with no evidence of treatment-related organ toxicity.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Ofatumumab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 24.00 and 25.15 ng/mL.
Chemical Information
-
CAS No. 679818-59-8
-
Appearance Liquid
-
Masse moléculaire 145.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Ofatumumab]
-
Synonyms
GSK1841157; OMB-157
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Barth MJ, et al. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma. Clin Cancer Res. 2015 Oct 1;21(19):4391-7. [Content Brief]
[2]. Barth MJ, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012 Feb;156(4):490-8. [Content Brief]
[3]. Sanford M, et al. Ofatumumab. Drugs. 2010;70(8):1013-1019. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ofatumumab Related Classifications
HY-P9961 Related Classifications
Powered by Bioz